Thermo Fisher Scientific (NYSE:TMO – Get Free Report) issued its quarterly earnings data on Wednesday. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41, reports. The company had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. Thermo Fisher Scientific updated its FY 2024 guidance to 21.140-22.020 EPS and its FY24 guidance to $21.14-22.02 EPS.
Thermo Fisher Scientific Trading Down 0.9 %
NYSE TMO opened at $572.10 on Friday. The company has a quick ratio of 1.39, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific has a twelve month low of $415.60 and a twelve month high of $603.82. The firm has a market capitalization of $218.38 billion, a PE ratio of 36.70, a P/E/G ratio of 2.44 and a beta of 0.80. The stock’s 50 day moving average is $573.08 and its 200 day moving average is $529.36.
Thermo Fisher Scientific Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is currently 10.01%.
Insider Activity at Thermo Fisher Scientific
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in TMO. Sumitomo Life Insurance Co. raised its holdings in shares of Thermo Fisher Scientific by 31.0% during the 1st quarter. Sumitomo Life Insurance Co. now owns 17,690 shares of the medical research company’s stock worth $9,709,000 after acquiring an additional 4,186 shares in the last quarter. Mesirow Financial Investment Management Inc. bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at approximately $53,063,000. MONECO Advisors LLC increased its position in shares of Thermo Fisher Scientific by 432.6% during the 1st quarter. MONECO Advisors LLC now owns 5,315 shares of the medical research company’s stock valued at $3,089,000 after purchasing an additional 4,317 shares during the last quarter. Petredis Investment Advisors LLC increased its position in shares of Thermo Fisher Scientific by 4.7% during the 1st quarter. Petredis Investment Advisors LLC now owns 7,298 shares of the medical research company’s stock valued at $4,242,000 after purchasing an additional 325 shares during the last quarter. Finally, Pine Haven Investment Counsel Inc bought a new position in shares of Thermo Fisher Scientific during the 1st quarter valued at approximately $218,000. 89.23% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday. Evercore ISI raised their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Barclays raised their price objective on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a report on Thursday. The Goldman Sachs Group raised their price objective on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Finally, HSBC raised their price objective on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average price target of $606.76.
View Our Latest Stock Analysis on TMO
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
- Five stocks we like better than Thermo Fisher Scientific
- What Are the U.K. Market Holidays? How to Invest and Trade
- How to Use Put Debit Spreads to Profit From Falling Stocks
- The 3 Best Blue-Chip Stocks to Buy Now
- Alphabet Changes the Narrative with Its First-Ever Dividend
- What is a Special Dividend?
- 5 High-Yielding Oversold Stocks with Bullish Ratings
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.